Price Target Changed • Jun 11
Price target increased by 7.2% to US$75.80 Up from US$70.73, the current price target is an average from 15 analysts. New target price is 17% above last closing price of US$64.75. Stock is up 85% over the past year. The company is forecast to post earnings per share of US$1.69 next year compared to a net loss per share of US$7.77 last year. Live News • Jun 11
Hinge Health Surpasses Q1 Expectations and Expands HingeSelect Into Orthopedic Surgery Hinge Health reported Q1 2026 revenue growth of 47% year over year, with adjusted EPS of $0.45 that exceeded expectations and supported higher full-year 2026 guidance for both revenue and margins.
The company plans to outline revised long-term operating model targets and future opportunities at its first Investor Day, held alongside the Movement conference on June 10.
Hinge Health expanded its HingeSelect offering to include orthopedic surgery, creating an end-to-end musculoskeletal care platform that spans conservative care, surgical evaluation, and post-operative recovery.
Taken together, the stronger-than-expected Q1 results and the expanded HingeSelect surgery offering indicate that the business is seeking to broaden its role in musculoskeletal care while refining its long-term model for growth and profitability.
Investors may want to watch the Investor Day closely for more detail on how the surgery component affects unit economics, capital needs, and the balance between software, hardware-assisted care, and higher-touch clinical services. Recent Insider Transactions Derivative • Jun 10
Co-Founder exercised options and sold US$3.3m worth of stock On the 5th of June, Gabriel Mecklenburg exercised options to acquire 50k shares at no cost and sold these for an average price of US$65.54 per share. This trade did not impact their existing holding. Since June 2025, Gabriel's direct individual holding has decreased from 3.16m shares to 2.16m. Company insiders have collectively sold US$53m more than they bought, via options and on-market transactions in the last 12 months. Announcement • Jun 03
Hinge Health, Inc. Announces Results of Digital Musculoskeletal Solution Study Hinge Health, Inc. announced the results of the most comprehensive medical claims analysis of its digital musculoskeletal (MSK) solution, demonstrating an average cost savings of $2,941 per member per year using its chronic MSK program and a 3.0x ROI for employers and health plans. The study analyzed claims data for more than 200,000 commercially-insured adults ages 18-64 across nearly 1,000 employers in 23 industries. Comparing Hinge Health members to a matched control group, the results are backed by scale, as well as long-term observation. The measurable outcomes show sustained savings over the course of five years from 2020 through 2024. Key findings include: 3.0x ROI: Hinge Health clients saved an average of $2,941 per member per year on overall MSK medical costs, tripling the return on average program fees. The program's ROI has consistently increased since 2020, reaching 3.14x for 2024. Hinge Health members had 69% fewer surgeries, 61% fewer injections, and 68% fewer imaging scans. 52% of savings came from lower surgery costs after members managed pain with fewer surgical interventions. Chronic MSK pain remains a leading cause of disability and healthcare costs in the United States. As medical claims for MSK conditions continue to rise, employers are increasingly focused on finding solutions that deliver measurable value. Hinge Health's model has been validated six times by third-party firms since 2022, each pressure testing across different demographics, periods of time, and lines of business. This study further empowers benefits leaders to assess the economic advantages of using Hinge Health to manage rising MSK costs. Live News • Jun 03
Hinge Health Surges on Strong Earnings Growth and Expansion Into Migraine Treatment Hinge Health reported quarterly revenue growth of 47% year over year, with margins and earnings ahead of expectations, and management raised both next-quarter guidance and the full-year forecast.
The stock moved up 10% in a single session following the earnings release, with Jim Cramer describing the results as a "true blowout set of numbers" on Mad Money.
One year after its IPO, Hinge Health shares are up 72%, supported by nearly 50% year-over-year revenue growth, stronger free cash flow, and FDA clearance for its Enzo wearable for migraine treatment, extending the business beyond musculoskeletal care.
Taken together, these updates point to a company that is pairing rapid top-line expansion with improving profitability metrics and a growing product portfolio in digital health.
Investors may want to keep an eye on how effectively Hinge Health integrates Enzo into its commercial offering and whether the pace of growth and free cash flow improvements can support the stock’s strong move since the IPO. Recent Insider Transactions Derivative • May 27
Chief Financial Officer notifies of intention to sell stock James Budge intends to sell 6k shares in the next 90 days after lodging an Intent To Sell Form on the 26th of May. If the sale is conducted around the recent share price of US$55.25, it would amount to US$326k. Since December 2025, James' direct individual holding has increased from 441.17k shares to 451.29k. Company insiders have collectively sold US$45m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • May 07
Co-Founder notifies of intention to sell stock Gabriel Mecklenburg intends to sell 300k shares in the next 90 days after lodging an Intent To Sell Form on the 6th of May. If the sale is conducted around the recent share price of US$49.75, it would amount to US$15m. Since June 2025, Gabriel's direct individual holding has decreased from 3.16m shares to 2.37m. Company insiders have collectively sold US$30m more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • May 06
First quarter 2026 earnings: EPS and revenues exceed analyst expectations First quarter 2026 results: EPS: US$0.43 (down from US$7.38 in 1Q 2025). Revenue: US$182.3m (up 47% from 1Q 2025). Net income: US$34.0m (down 72% from 1Q 2025). Profit margin: 19% (down from 98% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 5.9%. Earnings per share (EPS) also surpassed analyst estimates by 173%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Healthcare industry in the US. Announcement • May 01
Hinge Health Inc Introduces Migraine Care Program Hinge Health, Inc. introduced its Migraine Care Program, offering rapid drug-free pain relief, personalized trigger management, and expert-led prevention for members. With meaningful overlap between the treatments and clinical best practices for migraine and musculoskeletal (MSK) care, Hinge Health is leveraging its proven expertise in nerve stimulation, exercise therapy, and behavior change to deliver comprehensive, whole-person care for people living with migraine, MSK pain, or both. Migraine affects one in six Americans, with double the prevalence for women versus men. Approximately 75% of those who suffer from migraine pain also have MSK pain and the personal and financial burden is significant. People with migraine drive more than $16,000 in annual medical and pharmaceutical spend – over twice as much as those without migraine. Nationally, migraine costs U.S. businesses an estimated $78,000 million each year, and drives absenteeism and reduced productivity. The FDA recently cleared the proprietary Enso device for the treatment of migraine, enabling delivery of a first-of-its-kind care solution that combines groundbreaking technology with a full care team. The Hinge Health migraine care program will offer: Rapid, drug-free pain relief: Hinge Health's FDA-cleared Enso, a specialized wearable device designed for pain relief, now reduces migraine pain in minutes. Personalized trigger tracking & insights: AI-powered insights help members identify and manage migraine triggers across environmental, lifestyle, and dietary factors. Proactive prevention: Exercise therapy and lifestyle guidance led by expert care teams reduce the frequency and severity of migraine attacks, stopping the pain before it starts. To date, more than 125 clients covering more than two million people have adopted the Hinge Health Migraine Care Program, signaling that employers are ready to act on one of the leading causes of disability for people under 50 years of age. The Migraine Care Program will roll out in May 2026. Announcement • Apr 21
Hinge Health, Inc., Annual General Meeting, Jun 03, 2026 Hinge Health, Inc., Annual General Meeting, Jun 03, 2026. Announcement • Apr 03
Hinge Health, Inc. to Report Q1, 2026 Results on May 05, 2026 Hinge Health, Inc. announced that they will report Q1, 2026 results After-Market on May 05, 2026 Recent Insider Transactions Derivative • Mar 24
Chief Financial Officer notifies of intention to sell stock James Budge intends to sell 11k shares in the next 90 days after lodging an Intent To Sell Form on the 23rd of March. If the sale is conducted around the recent share price of US$42.48, it would amount to US$468k. Since June 2025, James' direct individual holding has increased from 172.29k shares to 412.43k. Company insiders have collectively sold US$30m more than they bought, via options and on-market transactions in the last 12 months. Announcement • Mar 18
Hinge Health, Inc. Appoints Tyler Sloat to Its Board of Directors Hinge Health, Inc. announced the addition of Tyler Sloat to its board of directors. Sloat currently serves as the Chief Financial Officer and Chief Operating Officer of Freshworks Inc., where he oversees accounting, finance, IT, security, workplace, corporate strategy and revenue enablement. As a seasoned executive and board member, Sloat has nearly three decades of operational leadership guiding high-growth technology companies through pivotal phases and rapid expansion. Prior to Freshworks, he was the CFO at Zuora, Inc., steering the business from its startup phase through its 2018 IPO. Previously, he held senior positions at NetApp, Inc. and Siebel Systems, Inc. and served on the boards of Oanda Corporation and Compass Healthcare. Recent Insider Transactions Derivative • Mar 08
Co-Founder & Executive Chairman notifies of intention to sell stock Gabriel Mecklenburg intends to sell 250k shares in the next 90 days after lodging an Intent To Sell Form on the 6th of March. If the sale is conducted around the recent share price of US$45.84, it would amount to US$11m. Since June 2025, Gabriel's direct individual holding has increased from 3.16m shares to 3.49m. Company insiders have collectively sold US$23m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Feb 24
Chief Financial Officer notifies of intention to sell stock James Budge intends to sell 15k shares in the next 90 days after lodging an Intent To Sell Form on the 23rd of February. If the sale is conducted around the recent share price of US$41.31, it would amount to US$610k. Since June 2025, James' direct individual holding has increased from 172.29k shares to 434.90k. Company insiders have collectively sold US$23m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Feb 13
Co-Founder notifies of intention to sell stock Daniel Perez intends to sell 167k shares in the next 90 days after lodging an Intent To Sell Form on the 12th of February. If the sale is conducted around the recent share price of US$38.76, it would amount to US$6.5m. For the year to December 2023, Daniel's total compensation was 98% salary and 2% non-salary. Since June 2025, Daniel's direct individual holding has increased from 10.52m shares to 14.93m. Company insiders have collectively sold US$16m more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Feb 11
Full year 2025 earnings: EPS and revenues exceed analyst expectations Full year 2025 results: US$9.68 loss per share (further deteriorated from US$0.88 loss in FY 2024). Revenue: US$587.9m (up 51% from FY 2024). Net loss: US$528.3m (loss widened US$516.3m from FY 2024). Revenue exceeded analyst estimates by 2.4%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Healthcare industry in the US. Announcement • Feb 11
Hinge Health, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2026 Hinge Health, Inc. provided earnings guidance for the first quarter and full year 2026. For the quarter, the company expects revenue to be between $171 million and $173 million, reflecting year over year growth of 39% at the midpoint.
For the full year, the company expects revenue to be between $732 million and $742 million, reflecting year over year growth of 25% at the midpoint. Announcement • Jan 14
Hinge Health, Inc. to Report Q4, 2025 Results on Feb 10, 2026 Hinge Health, Inc. announced that they will report Q4, 2025 results After-Market on Feb 10, 2026 Recent Insider Transactions Derivative • Jan 06
Co-Founder notifies of intention to sell stock Daniel Perez intends to sell 167k shares in the next 90 days after lodging an Intent To Sell Form on the 5th of January. If the sale is conducted around the recent share price of US$45.56, it would amount to US$7.6m. For the year to December 2023, Daniel's total compensation was 98% salary and 2% non-salary. Since June 2025, Daniel's direct individual holding has increased from 10.52m shares to 15.09m. Company insiders have collectively sold US$8.4m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Dec 16
Co-Founder notifies of intention to sell stock Daniel Perez intends to sell 167k shares in the next 90 days after lodging an Intent To Sell Form on the 15th of December. If the sale is conducted around the recent share price of US$49.70, it would amount to US$8.3m. For the year to December 2023, Daniel's total compensation was 98% salary and 2% non-salary. Since June 2025, Daniel's direct individual holding has increased from 10.52m shares to 15.26m. Company insiders have collectively sold US$273k more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Nov 21
Chief Financial Officer notifies of intention to sell stock James Budge intends to sell 45k shares in the next 90 days after lodging an Intent To Sell Form on the 20th of November. If the sale is conducted around the recent share price of US$44.10, it would amount to US$2.0m. Since June 2025, James' direct individual holding has increased from 172.29k shares to 525.25k. Company insiders have collectively sold US$216k more than they bought, via options and on-market transactions in the last 12 months. Announcement • Nov 12
Hinge Health, Inc. (NYSE:HNGE) announces an Equity Buyback for $250 million worth of its shares. Hinge Health, Inc. (NYSE:HNGE) announces a share repurchase program. Under the program, the company will repurchase up to $250 million worth of it shares. The Company expects to fund repurchases with existing cash and cash equivalents and ongoing cash from operations. Breakeven Date Change • Nov 05 The 14 analysts covering Hinge Health previously expected the company to break even in 2026. New consensus forecast suggests the company will make a profit of US$31.2m in 2026. Average annual earnings growth of 93% is required to achieve expected profit on schedule.
Announcement • Oct 22
Hinge Health Unveils New AI-Powered Care Tools Hinge Health, Inc. announced two AI-powered care tools: Movement Analysis uses computer vision to set a new standard for tracking musculoskeletal (MSK) outcomes, and Robin is an AI Care Assistant that provides instant support for members. Hinge Health also published its AI care principles, which guide the development of AI across its platform. There are many measurement tools to track outcomes in MSK care; while valuable - almost all rely on subjective questions and are therefore self-report only. Hinge Health’s new Movement Analysis uses TrueMotion® computer vision technology to guide members through targeted movements - capturing joint angles, symmetry, and endurance. Pairing those objective measurements with targeted questions creates first-of-its-kind Hinge Scores for joint health. This enables members to monitor their own progress and their relative performance compared to others. Meanwhile, clinicians gain a uniquely composite view to make faster, more impactful, and personalized treatment decisions. Announcement • Oct 02
Hinge Health, Inc. to Report Q3, 2025 Results on Nov 04, 2025 Hinge Health, Inc. announced that they will report Q3, 2025 results After-Market on Nov 04, 2025 Breakeven Date Change • Aug 06
Forecast to breakeven in 2026 The 13 analysts covering Hinge Health expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$4.57m in 2026. Average annual earnings growth of 99% is required to achieve expected profit on schedule. Announcement • Aug 06
Hinge Health, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2025 Hinge Health, Inc. provided revenue guidance for the third quarter and full year 2025. For the third quarter, the company expected revenue to be between $141 million and $143 million, reflecting year-over-year growth of 41% at the midpoint.
For the full year, the company expected revenue to be between $548 million and $552 million, reflecting year- over-year growth of 41% at the midpoint. Announcement • Jul 09
Hinge Health, Inc. to Report Q2, 2025 Results on Aug 05, 2025 Hinge Health, Inc. announced that they will report Q2, 2025 results After-Market on Aug 05, 2025 Valuation Update With 7 Day Price Move • Jul 07
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to US$43.07, the stock trades at a trailing P/E ratio of 24.7x. Average forward P/E is 13x in the Healthcare industry in the US. Valuation Update With 7 Day Price Move • Jun 20
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to US$42.07, the stock trades at a trailing P/E ratio of 24.2x. Average forward P/E is 13x in the Healthcare industry in the US. Announcement • Jun 18
Hinge Health, Inc. Announces HingeSelect- High-Performance Network Delivering Unified Musculoskeletal Care Hinge Health, Inc. announced the launch of HingeSelect, a high-performance provider network for musculoskeletal (MSK) care. Hinge Health's technology and in-house orthopedic physicians triage and direct downstream care, prioritizing the most appropriate evidence-based treatment. When in-person care, such as imaging or injections is required, members are seamlessly connected to pre-vetted providers at up to 50% below PPO rates. Combined with Hinge Health's AI-powered digital exercise therapy, HingeSelect provides members with end-to-end MSK care while reducing costs for employers and health plans. MSK conditions continue to rank as a top-two spend category for most employers. Orthopedic appointment wait times average 20 days, and adherence to evidence-based care can vary significantly among providers. Finally, even when care is appropriate, inflated unit costs continue to drive up expenses for employers and members alike. Hinge Health is integrating its innovative digital platform with HingeSelect's high-performance provider network, offering: Unified Care. Members benefit from a seamless blend of digital and in-person care. The technology triages people to receive the right treatment and drives adherence. When needed, in-house orthopedic specialists are available in as little as 48 hours to diagnose and manage care comprehensively. High-performance provider network. Members have access to a curated network of local physical therapists, imaging centers, and physicians delivering high-value care. Members will be able to schedule in-person appointments directly from app with visit records shared back with care team. Lower unit prices. Bundled pricing allows for transparent, predictable costs up to 50% below P PO rates and reduces member cost sharing. Announcement • May 22
Hinge Health, Inc. has completed an IPO in the amount of $437.312 million. Hinge Health, Inc. has completed an IPO in the amount of $437.312 million.
Security Name: Class A Common Stock
Security Type: Common Stock
Securities Offered: 13,666,000
Price\Range: $32
Discount Per Security: $2
Transaction Features: Sponsor Backed Offering 
